Heerspink, Hiddo J. L; Radhakrishnan, Jai; Alpers, Charles E; Barratt, Jonathan; Bieler, Stewart; Diva, Ulysses; Inrig, Jula; Komers, Radko; Mercer, Alex; Noronha, Irene de Lourdes 
Subjects: ALBUMINÚRIA, NEFROPATIAS, PROTEINÚRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, v. 401, n. 10388, p. 1584-1594, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54593. Acesso em: 08 nov. 2024.APA
Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., et al. (2023). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, 401( 10388), 1584-1594. doi:10.1016/S0140-6736(23)00569-XNLM
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2024 nov. 08 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593Vancouver
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2024 nov. 08 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593
